In this week's Health Data Ethics podcast, I dissected a 2023 JAMA study on using a voice-based AI tool to coach patients through insulin titration in type 2 diabetes. Big thanks up front to Aida McCracken who listened to me work through this one!

The results were encouraging—patients hit optimal dosing in 15 days vs. 56+ for standard care. But governance questions kept nagging me.

→ Self-titration works for insulin because it's clinically established. Try the same with other drugs and you're in much riskier territory.

→ Study was 8 weeks. Diabetes is lifelong. What happens when engagement drops or the smart speaker isn't supported anymore?

I'm all for empowering patients to follow validated protocols. We need scalable chronic disease solutions. But let's innovate with eyes open about equity, sustainability, and regulatory frameworks.